P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS

• Daniel Lopes De Menezes,
• Gail Roboz,
• Hartmut Döhner,
• Andrew Wei,
• Maria Teresa Voso,
• Andre Schuh,
• Wendy L. See,
• Manuel Ugidos,
• Arnaud Amzallag,
• Alberto Risueño,
• Kevin H. Eng,
• Rajasekhar Nvs Suragani,
• Barry Skikne,
• CL Beach,
• Thomas Prebet,
• Anita Gandhi

Affiliations

Daniel Lopes De Menezes

1 Bristol Myers Squibb, San Francisco, CA, United States

Gail Roboz

2 Weill Cornell Medicine, New York, NY, United States

Hartmut Döhner

3 Ulm University Hospital, Ulm, Germany

Andrew Wei

4 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia

Maria Teresa Voso

5 University of Rome Tor Vergata, Rome, Italy

Andre Schuh

6 Princess Margaret Cancer Centre, Toronto, Canada

Wendy L. See

1 Bristol Myers Squibb, San Francisco, CA, United States

Manuel Ugidos

7 BMS Center for Innovation and Translational Research Europe (CITRE, a Bristol-Myers Squibb Company), Seville, Spain

Arnaud Amzallag

8 Bristol Myers Squibb, Cambridge, MA, United States

Alberto Risueño

9 Bristol Myers Squibb, Lawrenceville, NJ, United States

Kevin H. Eng

10 Bristol Myers Squibb, Princeton, NJ, United States

Rajasekhar Nvs Suragani

8 Bristol Myers Squibb, Cambridge, MA, United States

Barry Skikne

11 University of Kansas Cancer Center, Kansas City, KS, United States

CL Beach

13 Bristol Myers Squibb, Summit, NJ, United States

Thomas Prebet

13 Bristol Myers Squibb, Summit, NJ, United States

Anita Gandhi

13 Bristol Myers Squibb, Summit, NJ, United States